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Abstract
Background: Genetic susceptibility plays a key role in the development of nasopharyngeal carcinoma (NPC) and
in fact the disease presents with an unusually high incidence in certain regions of the world like North Africa. We
investigated the association between polymorphism of the Transforming growth factor-β1 (TGF-β1) and risk of
NPC in North Africa. TGF-β1 is a multifunctional cytokine that acts as both a tumor suppressor and a stimulator of
cancer development; it has been shown to influence risk of numerous other carcinomas including lung, breast
and prostate cancer.
Methods: TGF-β1 polymorphisms C-509T and T869C were studied in a large North African sample of 384 NPC
cases and 361 controls, matched for age, sex and urban or rural residence in childhood. Genotypes were determined
using polymerase chain reaction–restriction fragment length polymorphism.
Results: No association was observed between individual single nucleotide polymorphisms or their haplotypes and
NPC susceptibility (for TGF-β1 C-509T: OR = 0.74; 95 % CI 0.46 − 1.18; for TGF-β1 T869C: OR = 0.86; 95 % CI 0.56 − 1.31),
even when the samples were stratified by age, gender and TNM stage.
Conclusion: Contrary to what has been observed in Asian samples, in our North African sample, the TGF-β1 C-509T
and T869C polymorphisms did not substantially influence NPC susceptibility.
Keywords: Nasopharyngeal carcinoma, TGF-β1, Single nucleotide polymorphisms, Genetic susceptibility, North African
population
Background
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy arising from the mucosal epithelium of the naso-
pharynx [1]. It is a highly invasive and metastatic malignant
tumor that differs significantly from other cancers of the
head and neck in its distinct geographical distribution,
causes, occurrence and clinical attributes [2, 3]. Both envir-
onmental factors (Epstein Barr virus & dietary factors) and
genetic susceptibility play roles in the development of NPC
[4, 5]. Although it is a rare malignancy in most parts of the
world, NPC is endemic in a few well-defined populations
such as those native in Southeast Asia, where the incidence
is nearly 20–60 times higher than that reported in Western
countries [6–8]. In North Africa, NPC is one of the most
common head and neck cancers with an incidence rate
around 3.5–10 per 100,000 inhabitants. In contrast to
high-risk areas of Asia, the age-incidence curve in this
intermediate-risk area is bimodal, with a first peak in
the teens and a second at 45–60 years [9, 10].
Transforming growth factor-β1 (TGF-β1) is the most
abundant isoform of the TGF-β and can regulate both
immune system and cellular functions [11–13]. The
TGF-β1 gene is located on chromosome 19q13.1–3
[14, 15]. Hundreds of single nucleotide polymorphisms
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have been reported for TGF-β1 and several of them are
functional [16, 17]. The genetic variants of the TGF-β1
gene have been implicated in the susceptibility of a large
range of carcinoma, including lung cancer [18], oropha-
ryngeal cancer [19], prostate cancer [20] and breast cancer
[21, 22]. The C-509T and T869C are the most commonly
studied polymorphisms since it has been shown that
they affect the expression of the TGF-β1 protein and
gene–dose effects have been observed [23–25]. It has
been reported that NPC patients display a lower level
of TGF-β1 in plasma and a higher level in tumor tis-
sues and surrounding stroma compared to healthy con-
trols [26–28]. To date, three studies have investigated
the association between TGF-β1 and NPC. They all fo-
cused on the C-509T and T869C polymorphisms and
were all conducted in Chinese populations. In 2007,
Wei et al. studying a sample of 108 NPC cases and 120
controls reported a significant increase of risk for the
-509T allele (OR = 1.64) as well as for the 869C allele
(OR = 1.70) [29]. In 2012, Hu et al. studying a sample
of 522 NPC cases and 712 controls reported a significant
decrease of risk for the −509T allele (OR = 0.67) and no
association with the T869C polymorphism. Furthermore
they showed that the −509C allele drive an ~1.7-fold in-
crease of TGF-β1 expression in NPC cell lines [30]. In
2014, Qu et al. studying a sample of 194 cases and 231
controls did not report any significant association with
NPC [31]. In view of these results it seemed relevant to
study further the association of the TGF-β1 C-509T and
T869C polymorphisms with NPC risk. The present study




Details of the sample used here, 384 NPC cases and 361
controls from the IARC (International Agency for Research
on Cancer) international study of NPC are described else-
where [4, 32]. Briefly, all cases and controls were recruited
in the three North African countries Morocco, Algeria and
Tunisia where NPC incidence is the highest. Inclusion
criteria stipulated that all four grandparents of each
subject were of Moroccan, Algerian or Tunisian origin
in order to avoid all risk of admixture bias. The control
group consisted of unrelated subjects frequency matched
with cases on recruitment center, sex, age and household
in childhood (urban or rural). Detailed demographic and
epidemiologic data as well as blood samples were obtained
from each subject at time of recruitment using a question-
naire designed at the International Agency for Research
on Cancer. All subjects gave informed consent for the
study, and the International Agency for Research on
Cancer ethical committee approved the study.
DNA extraction and genotyping
The peripheral venous blood was collected from all en-
rolled NPC patients and controls. Genomic DNA was
extracted from the peripheral venous blood using the
proteinase K digestion and phenol–chloroform extrac-
tion or using the Gentra Puregene Blood Kit.
The TGF-β1 C-509T and T869C genotypes were deter-
mined by using a polymerase chain reaction–restriction
fragment length polymorphism method. As published by
Kang et al. [18], the PCR primers for the C-509T
(rs1800469) and T869C (rs1800470) polymorphisms were
5′- GGGTCCCTCTGGGCCCAGTT-3′ (forward) and
5′-GGGGGCAACAGGACACCCGA-3′ (reverse); and
5′-ACCACACCAGCCCTGTTC- 3′ (forward) and 5′-
GATGGCCTCGATGCGCTT-3′ (reverse), respectively.
The PCRs were performed in a total volume of 25 μl
containing ~ 50 ng genomic DNA, 0.2 mM dNTP, 2.0 mM
MgCl2, 0.25 μM each primer, and 1 unit of Taq polymer-
ase (Go Taq DNA Polymerase, Promega). The PCR cycle
conditions consisted of an initial denaturation step at
95 °C for 5 min followed by 35 cycles of 35 s at 94 °C;
30 s at 60 °C for C-509T and 58 °C for T869C; 30 s at
72 °C; and a final elongation at 72 °C for 7 min. The
PCR products were incubated overnight at 37 °C with
the appropriate restriction enzymes. The restriction en-
zymes for the C-509T and T869C genotypes were AvaI
and MspA1I, respectively. The digested PCR products
were resolved on 2 and 6 % agarose gel respectively and
stained with Ethidium Bromide for visualization under
U.V light.
Quality control
A random sample representing 20 % of the cases and
controls was blindly tested twice by different investigators,
and the results were concordant for all duplicate sets.
Statistical analysis
Genotype and allele frequencies of TGF-β1 were compared
between NPC cases and controls using the Chi-squared
(χ2) test, the odds ratios (OR) and 95 % confidence in-
tervals (CIs) were calculated to assess the relative risk.
Hardy-Weinberg equilibrium was tested for with a
goodness of fit χ2 test with one degree of freedom to
compare the observed genotype frequencies among the
subjects with the expected genotype frequencies. The
linkage disequilibrium (LD) between the polymorphisms
was quantified using Haploview 4.2 software. The SPSS
20.0 statistical software package (Chicago, IL) was used for
statistical analysis. The haplotypes and their frequencies
were estimated using the HAPSTAT 3.0 software. Stat-
istical significance was assumed at the P < 0.05 level.
Power calculation was performed using the University
of British Columbia tool for power calculation (http://
www.stat.ubc.ca/~rollin/stats/ssize/).
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Results
The demographics of the cases and controls are shown
in Table 1.
The genotypes and alleles frequencies of the TGF-β1
C-509T and T869C polymorphisms among the controls
and the cases are shown in Table 2. Haplotype analyses
were performed and the possible four haplotype fre-
quencies are shown in Table 3. Genotypic distributions
were in Hardy-Weinberg equilibrium in cases and in
controls (P > 0.05) and the two polymorphisms were in
relatively strong linkage disequilibrium (LD), |D′| = 0.65.
None of the polymorphisms studied nor their haplotypes
appeared to be associated with NPC risk.
As cases from the first age incidence peak (≤30) are
believed to have a strongest genetic susceptibility, we
tested association between NPC risk and TGF-β1 C-509T
and T869C polymorphisms in the subgroups ≤30 and
>30 year of age. No significant association was observed
(Table 4).
As NPC is more frequent among men than women
[33, 34], we also stratified the analysis by sex but no as-
sociation between the two polymorphisms and NPC risk
was observed (Table 4).
Assuming that TGF-β1 plays a dual role in tumor sup-
pression and oncogenesis [13, 35], we examined the as-
sociation between the two TGF-β1 polymorphisms with
TNM stage. However, no significant differences were
found (Additional file 1: Table S1).
Table 1 Characteristics of the study population
Characteristics Cases n (%) Controls n (%) P-valuea
Whole sample 384 361
Gender
Male 263 (68.49) 243 (67.31) 0.731
Female 121 (31.51) 118 (32.69)
Age mean (years) 42.24 43.58
Age
≤30 101 (26.30) 83 (22.99) 0.295
>30 283 (73.70) 278 (77.01)
Country
Tunisia 190 (49.48) 172 (47.65) 0.852
Morocco 180 (46.88) 174 (48.20)
Algeria 14 (3.65) 15 (4.16)
TNM stageb
I 0 -
II 13 (4.55) -
III 65 (22.73) -
IV 208 (72.73) -
aP-value of χ2 comparing cases and controls
bTNM was missing for 98 cases out of 384
Table 2 Genotype and allele distributions of TGF-β1 polymorphisms in NPC cases and controls. Odd Ratios obtained by univariate
and multivariate analyses
Polymorphism Cases n (%) Controls n (%) OR (CI 95 %)a P-value OR (CI 95 %)b P-value
TGF-β1 −509
Genotype
CC 127 (39.20) 120 (37.03) 1.00 - 1.00 -
CT 153 (47.22) 148 (45.68) 0.97 (0.69–1.36) 0.891 0.97 (0.69–1.37) 0.879
TT 44 (13.58) 56 (17.29) 0.74 (0.46–1.18) 0.211 0.73 (0.45–1.17) 0.194
Allele
C 407 (62.47) 388 (59.87) 1.00 - 1.00 -
T 241 (37.53) 260 (40.12) 0.88 (0.70–1.10) 0.278 0.87 (0.70–1.10) 0.251
TGF–β1 869
Genotype
TT 132 (36.57) 119 (35.52) 1.00 - 1.00 -
TC 165 (45.70) 149 (44.48) 0.99 (0.71–1.39) 0.992 0.99 (0.71–1.38) 0.955
CC 64 (17.72) 67 (20.00) 0.86 (0.56–1.31) 0.488 0.80 (0.52–1.23) 0.312
Allele
T 429 (59.91) 387 (57.76) 1.00 - 1.00 -
C 293 (40.09) 283 (42.23) 0.93 (0.75–1.15) 0.530 0.92 (0.75–1.14) 0.453
n number of subjects
aUnadjusted Odds ratios and confidence interval for case-control comparison
bOdds ratios and confidence interval adjusted on age, sex and country
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Discussion
To date, the effect of the TGF-β1 gene on NPC suscepti-
bility has been explored in only three case-control studies,
all of them conducted in Chinese samples, but the results
were conflicting. Wei et al. reported that the −509T and
869C alleles were associated with a significant increase of
risk while Hu et al. [30] found that the −509T allele
was associated with a reduced risk (and no association
was observed with T869C). Finally, Qu et al. [31] found
no association while they had the statistical power to
find associations of the size of the ones described by
Wei et al. [29].
In our North African sample, we did not find any sig-
nificant associations between C-509T and T869C and
risk of NPC, while we had the power to find association
of the size of the ones reported previously. Our sample
conferred 80 % power to detect OR above 1.37 or below
0.72 for the −509T allele and above 1.35 for the 869C
allele.
The frequencies of the TGF-β1 alleles studied in our
North African sample were quite similar to the one re-
ported in the Chinese samples. Frequencies of the −509T
and 869C were 0.401 and 0.422, respectively among our
North African controls compared to 0.508 and 0.496 in
Wei et al. control group, 0.478 and 0.488 in Hu et al. con-
trol group and 0.480 and 0.471 in Qu et al. control group
[29–31]. These frequencies are higher than those observed
among European Caucasians (0.110 and 0.180 respectively
in a Spanish sample [36]; 0.102 and 0.171 in a Czech sam-
ple [37]). We also measured the LD between the two
Table 3 Haplotype distribution of TGF-β1 polymorphisms in NPC cases and controls
Haplotype TGF-β1 −509–TGF-β1 869 Cases 2n = 600 (%) Controls 2n = 598 (%) OR (CI 95 %)a P-value
C– T 295 (49.17) 304 (50.84) 1.00 -
T– C 190 (31.67) 183 (30.60) 1.07 (0.82–1.38) 0.608
C– C 69 (11.50) 60 (10.03) 1.18 (0.80–1.73) 0.382
T– T 46 (7.66) 51 (8.53) 0.92 (0.60–1.43) 0.738
n number of subjects
aUnadjusted Odds ratios and confidence interval for case-control comparison
Table 4 Distribution of TGF-β1 polymorphisms genotypes according to age and sex in NPC cases and controls
≤30 >30
Genotype Cases n (%) Controls n (%) OR (CI 95 %)a P-value Cases n (%) Controls n (%) OR (CI 95 %)a P-value
TGF-β1 −509
CC 26 (30.23) 30 (38.96) 1.00 - 101 (42.44) 90 (36.44) 1.00 -
CT 42 (48.84) 31 (40.26) 1.56 (0.77–3.15) 0.211 111 (46.64) 117 (47.37) 0.85 (0.58–1.24) 0.392
TT 18 (20.93) 16 (20.78) 1.30 (0.55–3.05) 0.549 26 (10.92) 40 (16.19) 0.58 (0.32–1.02) 0.060
TGF-β1 869
TT 32 (34.04) 23 (29.49) 1.00 - 100 (37.45) 96 (37.35) 1.00 -
CT 44 (46.81) 42 (53.85) 0.75 (0.38–1.49) 0.415 121 (45.32) 107 (41.63) 1.09 (0.74–1.59) 0.674
CC 18 (19.15) 13 (16.67) 0.99 (0.41–2.43) 0.992 46 (17.23) 54 (21.01) 0.82 (0.50–1.32) 0.414
Men Women
Genotype Cases n (%) Controls n (%) OR (CI 95 %)a P-value Cases n (%) Controls n (%) OR (CI 95 %)a P-value
TGF-β1 −509
CC 88 (40. 00) 82 (37.27) 1.00 - 39 (37.50) 38 (36.54) 1.00 -
CT 100 (45.45) 95 (43.18) 0.98 (0.65–1.48) 0.927 53 (50.96) 53 (50.96) 0.97 (0.54–1.75) 0.931
TT 32 (14.55) 43 (19.55) 0.69 (0.40–1.20) 0.190 12 (11.54) 13 (12.50) 0.90 (0.36–2.22) 0.818
TGF-β1 869
TT 90 (36.00) 80 (36.20) 1.00 - 42 (37.84) 39 (34.21) 1.00 -
CT 105 (42.00) 94 (42.53) 0.99 (0.66–1.50) 0.973 60 (54.05) 55 (48.25) 1.01 (0.57–1.80) 0.965
CC 55 (22.00) 47 (21.27) 1.04 (0.63–1.70) 0.875 9 (8.11) 20 (17.54) 0.42 (0.17–1.03) 0.057
n number of subjects
aUnadjusted Odds ratios and confidence interval for case-control comparison
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polymorphisms studied and found that its extent in con-
trol subjects in China [29] (|D′| = 0.914) was stronger than
that in our study (|D′| = 0.65) and in Caucasian subjects
from the UK (|D′| = 0.737) [38]. In addition, the frequen-
cies of the two major haplotypes −509C/869T and −509T/
869C among our controls were 0.508 and 0.306,
respectively, which was relatively similar to those
observed in the Chinese samples (0.429 and 0.433,
respectively) [29] and the UK sample (0.640 and
0.240, respectively) [39].
Our study has both strengths and limitations. Its rigor-
ous case-control design (with matching of cases and
controls and check on the ethnicity of the four grand
parents of each subject) and the detailed epidemiological
and clinical evaluation are its main strength. The sample
size is quite large in regards of the incidence of NPC in
North Africa; 4 years of recruitment in six centers across
three countries were necessary to gather the sample
studied here. However, the sample size remains limited
and it is possible that in a larger sample, and with more
SNP’s studied, one could detect a significant association
between TGF-β1 polymorphism and NPC risk.
To date studies of TGF-β1 C-509T and T869C polymor-
phisms effects on risks of cancers such as hepatocellular
carcinoma [40, 41], breast cancer [22, 42], gastric cancer
[43, 44], and esophageal squamous cell carcinoma (ESCC)
[45, 46] have also yielded somewhat conflicting results.
For example medium size studies of ESCC (including
about 250 cases) performed in Chinese samples resulted
for one in the 869C allele to be associated with increased
risk of ESCC while C-509T was not associated [45] and
for the other study, in T869C not to be associated while
the −509T allele was associated with reduced risk [46].
Recruitment biases and small sample sizes may explain
the discrepancies observed. However, variations in
genetic backgrounds and environmental factors among
populations might also generate discrepancies. The
function of the TGF-β1 protein is complex and the
true relationship between TGF-β1 and NPC may be
modulated by gene-gene or gene-environment interac-
tions. Cancer is a multifactorial disease and variations
across populations in environmental exposure and genetic
susceptibility may generate unclear results in association
studies. The results obtained so far highlight the need to
perform studies on large-size samples and in various
geographic areas.
Conclusions
Our results suggest that the TGF-β1 C-509T and T869C
polymorphisms are not associated to NPC susceptibility
in the North African population, or if such an association
exists it is too weak to be detected with a sample of 384
cases and 361 controls.
Additional file
Additional file 1: Table S1. Association of TGF-β1 gene polymorphisms
with TNM stage. (DOCX 21 kb)
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